In the recent years, NIPD has found new applications in monogenic diseases diagnostic for paternally inherited mutations. Such an approach remains very challenging because of the inherent limitations of molecular testing methods, the low concentration of circulating free fetal DNA (cff-DNA) in maternal plasma and the "maternal contamination". We developed and evaluated an NIPD test for Cystic Fibrosis for the most common French mutation. It consists in searching the paternal mutation in compound heterozygous families using MEMO-PCR method (Lee et al 2011) associated with real-time PCR. The analytical validation step was made on chimeric DNA control samples that contain 0%, 2%, 5%, 10%, 50% and 100% of mutant DNA at a final concentration of 100 pg/mL. In addition, we have assessed a mini STR kit as quality control to confirm the presence of cff DNA in the maternal plasma. We obtained the first proofs of concept of our approach by the accuracy for the detection of the p.Gly542* mutation. Real-time MEMO PCR demonstrated the blocking efficiencies of normal allele with an enrichment of mutant allele and reveals differences in melting curve shape that correlate with the nature of each chimeric sample with a detection threshold of 2%. A tri-allelic profile was found for all tested maternal plasma.
Our new approach offers numerous advantages: it is simple, cost and time efficient, and applicable to different type of variants: point mutations or small insertion/deletions. Therefore, this method does not require complex equipment or bioinformatics setting and can be easily applicable in routine. Nevertheless validation studies are necessary to be manageable in clinical practice. Idiopathic pancreatitis is a multigenic and multifactorial disease. Genetically determined pancreatitis is associated with PRSS1, SPINK1 and CFTR mutations. This study aims at investigating clinical and morphological characteristics of patients diagnosed with genetically determined sporadic pancreatitis. Inclusion criteria were the presence of PRSS1, CFTR or SPINK1 mutations in patients with idiopathic or chronic pancreatitis. Patients with hereditary pancreatitis were excluded. Ageand gender-matched patients with idiopathic pancreatitis and negative genetic testing served as controls (n = 68). Genetic testing was performed in 351 referrals to our centre since 1999. Of these, 61 (17.4%) carried at least one mutation (34 CFTR, 10 PRSS1 and 13 SPINK1), while four showed a combination of mutations. Follow-up has been extended to a median of 5 (range 1−40) years. Similar clinical features were noted in cases and controls except for an earlier age of onset of pancreatic symptoms and a higher incidence of pancreatic cancer in patients with CFTR mutations compared with controls (p < 0.05). The ratio of observed to expected pancreatic cancers averaged 26.5 (95% CI: 8.6-61.9). All pancreatic cancer patients were smokers. Except for an earlier age of onset of pancreatic disease, clinical features of patients with sporadic idiopathic pancreatitis and gene mutations were similar to those of controls. A significantly higher occurrence of pancreatic cancer was observed in patients carrying CFTR mutations. We therefore suggest including patients with CFTR variants and risk factors into a screening and surveillance program, while strongly advising them to stop smoking.
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